Viyash Scientific (VIYASH) AI Stock Analysis

4 Followers

Viyash Scientific

(NSE:VIYASH)

Select Model

Rating:57Neutral

Price Target:INR 246.00▼(-3.02% Downside)

Action:reiterated

Date:08/21/26

The overall score reflects a company with an improving but still transitional financial profile, where the FY2026 rebound in revenue, margins, and cash generation is offset by a volatile earnings history and uneven cash flow quality. Technicals modestly enhance the score, with price action above key moving averages but only neutral momentum and higher beta-driven volatility. A rich P/E multiple without supporting dividend yield data weighs on the final score, indicating that the stock’s valuation is ahead of its demonstrated consistency, keeping the rating in the mid-range rather than at a premium level.

Positive Factors

Revenue and Margin ExpansionThe combination of dramatic 2026 revenue growth and higher EBIT and EBITDA margins indicates improving operating scale and profitability. If maintained, this stronger earnings base can support reinvestment, improve resilience, and establish a more competitive position over the next several quarters.

Negative Factors

Earnings VolatilityRecent profitability has not yet demonstrated consistent stability because the company experienced losses in 2023–2024 and negative EBIT margins during that period. Continued volatility could make earnings harder to forecast and weaken confidence that current margins represent a durable operating level.

Viyash Scientific (VIYASH) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 112.70B
Dividend Yield: ―
Average Volume (3M): 369.25K
Price to Earnings (P/E): 60.8
Beta (1Y): 1.07
Revenue Growth: 96.48%
EPS Growth: 251.87%
Country: India
Employees: 1,244
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Viyash Scientific Business Overview & Revenue Model

Company Description

Viyash Scientific Limited is a global veterinary healthcare company with operations spanning Europe, Asia, and other international markets. It specializes in developing and supplying finished dosage forms for a range of therapeutic applications, incl...

Viyash Scientific Financial Statement Overview

Summary

Financial performance is moderately strong, reflecting a clear FY2026 turnaround in revenue, margins, and cash generation, but constrained by volatile past results, a prior loss, uneven returns, and still-improving cash flow quality.

Income Statement

58Neutral

Balance Sheet

66Positive

Cash Flow

54Neutral

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	31.49B	34.20B	15.51B	13.66B	14.18B	14.10B
Gross Profit	10.67B	10.58B	7.40B	5.53B	1.59B	5.66B
EBITDA	5.84B	6.54B	1.59B	549.80M	-464.48M	1.18B
Net Income	1.71B	1.77B	218.80M	-358.69M	-1.21B	409.55M
Balance Sheet
Total Assets	0	46.28B	16.02B	15.40B	15.29B	14.51B
Cash, Cash Equivalents and Short-Term Investments	2.59B	2.70B	632.04M	687.85M	416.25M	591.21M
Total Debt	0	4.90B	4.81B	4.88B	4.44B	3.65B
Total Liabilities	-31.15B	15.14B	8.32B	8.27B	7.80B	7.11B
Stockholders Equity	31.15B	29.11B	7.04B	6.57B	6.99B	6.92B
Cash Flow
Free Cash Flow	288.00M	1.29B	442.70M	-2.12M	-693.71M	-18.69M
Operating Cash Flow	449.00M	2.64B	833.60M	305.95M	168.08M	305.95M
Investing Cash Flow	-42.20M	-938.90M	-247.80M	-119.05M	-649.58M	-955.66M
Financing Cash Flow	-325.70M	-543.10M	-607.30M	45.46M	322.28M	672.57M

Viyash Scientific Technical Analysis

Technical Analysis SentimentPositive

Last Price253.65

Price Trends

50DMA239.01Positive

100DMA253.80Negative

200DMA234.70Positive

Market Momentum

MACD0.15Negative

RSI65.45Neutral

STOCH86.86Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIYASH, the sentiment is Positive. The current price of 253.65 is above the 20-day moving average (MA) of 224.12, above the 50-day MA of 239.01, and above the 200-day MA of 234.70, indicating a bullish trend. The MACD of 0.15 indicates Negative momentum. The RSI at 65.45 is Neutral, neither overbought nor oversold. The STOCH value of 86.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VIYASH.

Viyash Scientific Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:VIYASH against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:CAPLIPOINT	85Outperform	INR 190.11B	28.79	―	0.32%	15.01%	17.73%
IN:ALIVUS	76Outperform	INR 181.43B	26.68	―	0.34%	8.19%	26.12%
IN:AKUMS	73Outperform	INR 120.46B	32.40	―	0.39%	17.50%	14.74%
IN:APLLTD	71Outperform	INR 200.09B	24.00	―	1.16%	19.68%	33.03%
IN:STAR	67Neutral	INR 92.37B	14.94	―	0.50%	11.28%	55.18%
IN:VIYASH	57Neutral	INR 104.93B	60.77	―	―	96.48%	251.87%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

IN:VIYASH and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:VIYASH	Viyash Scientific Limited	253.65	24.90	10.89%
IN:AKUMS	Akums Drugs and Pharmaceuticals Limited	769.80	334.76	76.95%
IN:APLLTD	Alembic Pharmaceuticals Limited	1029.65	125.80	13.92%
IN:CAPLIPOINT	Caplin Point Laboratories Limited	2520.95	588.91	30.48%
IN:ALIVUS	Glenmark Life Sciences Limited	1453.40	553.37	61.48%
IN:STAR	Strides Pharma Science Ltd	999.15	29.89	3.08%

Viyash Scientific Corporate Events

Viyash Scientific Publishes Q1 FY’27 Earnings Call Transcript for Investors

Aug 16, 2026

Viyash Scientific Limited has notified stock exchanges about the availability of its Q1 FY’27 earnings call transcript for the quarter ended June 30, 2026. The disclosure, made under Regulation 30 of India’s listing obligations framework, covers unau...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 21, 2026

Viyash Scientific AI Stock Analysis